Discovery and Mechanistic Investigation of a Novel Kinase Inhibitor Targeting EGFR Resistance Mutations.
BACKGROUND The Epidermal Growth Factor Receptor (EGFR) serves as a core target in tumor-targeted therapy. Mutations in EGFR frequently lead to resistance against clinical Tyrosine Kinase Inhibitors (TKIs), underscoring the critical need to develop novel EGFR-targeting compounds for overcoming drug resistance. METHODS...